OBJECTIVE: Genetic aberration such as the amplification of c-myc has been commonly found in advanced prostate cancer. The aim of this study was to elucidate chromosome 8 alteration, including a gain and amplification of 8q24 (c-myc gene), related to the progression and survival in advanced (Stage C) prostate cancer. MATERIALS AND METHODS: We used dual-probe fluorescence in situ hybridization with a centromere-specific probe for chromosome 8 (8cen), and with a region-specific probe for c-myc (8q24) to evaluate genetic changes in tumor samples from 50 patients who had undergone radical retropubic prostatectomy from 1986 to 2001. RESULTS: We classified the 8cen and c-myc copy numbers as normal, gain and amplification. The carcinoma foci with extra copies of c-myc, which was defined in 35 cases (70%), were divided into two groups: (a) a simple gain of the whole chromosome 8 (no increase in the c-myc copy number relative to the chromosome 8 centromere), which was identified in 15 cases (30%); and (b) a substantial amplification of c-myc (additional increases [AI] in the c-myc copy number relative to the chromosome 8 centromere), which was detected in 20 cases (40%). AI-c-myc was strongly associated with higher histopathological grades and Gleason's scores (P = 0.0330, 0.0190, respectively). Patients with the AI-c-myc had earlier disease progression (P = 0.0029) and earlier cancer death (P = 0.0087) than did patients with normal patterns. CONCLUSION: Identification of an AI-c-myc may serve as a potential marker of prostate cancer progression.
OBJECTIVE: Genetic aberration such as the amplification of c-myc has been commonly found in advanced prostate cancer. The aim of this study was to elucidate chromosome 8 alteration, including a gain and amplification of 8q24 (c-myc gene), related to the progression and survival in advanced (Stage C) prostate cancer. MATERIALS AND METHODS: We used dual-probe fluorescence in situ hybridization with a centromere-specific probe for chromosome 8 (8cen), and with a region-specific probe for c-myc (8q24) to evaluate genetic changes in tumor samples from 50 patients who had undergone radical retropubic prostatectomy from 1986 to 2001. RESULTS: We classified the 8cen and c-myc copy numbers as normal, gain and amplification. The carcinoma foci with extra copies of c-myc, which was defined in 35 cases (70%), were divided into two groups: (a) a simple gain of the whole chromosome 8 (no increase in the c-myc copy number relative to the chromosome 8 centromere), which was identified in 15 cases (30%); and (b) a substantial amplification of c-myc (additional increases [AI] in the c-myc copy number relative to the chromosome 8 centromere), which was detected in 20 cases (40%). AI-c-myc was strongly associated with higher histopathological grades and Gleason's scores (P = 0.0330, 0.0190, respectively). Patients with the AI-c-myc had earlier disease progression (P = 0.0029) and earlier cancer death (P = 0.0087) than did patients with normal patterns. CONCLUSION: Identification of an AI-c-myc may serve as a potential marker of prostate cancer progression.
Authors: Dominique Trudel; Gaetano Zafarana; Jenna Sykes; Cherry L Have; Robert G Bristow; Theo van der Kwast Journal: J Histochem Cytochem Date: 2013-05-02 Impact factor: 2.479
Authors: Masafumi Toyoshima; Heather L Howie; Maki Imakura; Ryan M Walsh; James E Annis; Aaron N Chang; Jason Frazier; B Nelson Chau; Andrey Loboda; Peter S Linsley; Michele A Cleary; Julie R Park; Carla Grandori Journal: Proc Natl Acad Sci U S A Date: 2012-05-23 Impact factor: 11.205
Authors: Kerstin M Heselmeyer-Haddad; Lissa Y Berroa Garcia; Amanda Bradley; Leanora Hernandez; Yue Hu; Jens K Habermann; Christoph Dumke; Christoph Thorns; Sven Perner; Ekaterina Pestova; Catherine Burke; Salim A Chowdhury; Russell Schwartz; Alejandro A Schäffer; Pamela L Paris; Thomas Ried Journal: Am J Pathol Date: 2014-08-14 Impact factor: 4.307
Authors: Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer Journal: Gynecol Oncol Date: 2009-06-12 Impact factor: 5.482
Authors: Michael Pourdehnad; Morgan L Truitt; Imran N Siddiqi; Gregory S Ducker; Kevan M Shokat; Davide Ruggero Journal: Proc Natl Acad Sci U S A Date: 2013-06-26 Impact factor: 12.779
Authors: Anshu Rastogi; Shyh-Han Tan; Ahmed A Mohamed; Yongmei Chen; Ying Hu; Gyorgy Petrovics; Taduru Sreenath; Jacob Kagan; Sudhir Srivastava; David G McLeod; Isabell A Sesterhenn; Shiv Srivastava; Albert Dobi; Alagarsamy Srinivasan Journal: Genes Cancer Date: 2014-07